

Stephen T Sonis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/708213/publications.pdf>

Version: 2024-02-01

171
papers

13,674
citations

41627

51
h-index

25983

112
g-index

176
all docs

176
docs citations

176
times ranked

8823
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. <i>Oral Diseases</i> , 2022, 28, 9-22.	1.5	17
2	The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 57-77.	157.7	60
3	Increasing HPV vaccination coverage to prevent oropharyngeal cancer: A cost-effectiveness analysis. <i>Tumour Virus Research</i> , 2022, 13, 200234.	1.5	4
4	Oral lichen planus: comparative efficacy and treatment costs—a systematic review. <i>BMC Oral Health</i> , 2022, 22, 161.	0.8	20
5	Industry and MASCC—an opportunity not to be missed. <i>Supportive Care in Cancer</i> , 2021, 29, 559-561.	1.0	1
6	Network meta-analysis from a pairwise meta-analysis design: to assess the comparative effectiveness of oral care interventions in preventing ventilator-associated pneumonia in critically ill patients. <i>Clinical Oral Investigations</i> , 2021, 25, 2439-2447.	1.4	2
7	Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women's Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019. <i>Cancer</i> , 2021, 127, 1796-1804.	2.0	22
8	Treatment for Oral Mucositis—Current Options and an Update of Small Molecules Under Development. <i>Current Treatment Options in Oncology</i> , 2021, 22, 25.	1.3	12
9	Benefits of the Involvement of Dentists in Managing Oral Complications Among Patients With Oral Cavity and Oropharyngeal Cancer: An Analysis of Claims Data. <i>JCO Oncology Practice</i> , 2021, 17, e1668-e1677.	1.4	3
10	Exceptional toxicity resistance. <i>Supportive Care in Cancer</i> , 2021, 29, 2263-2264.	1.0	2
11	Superoxide Dismutase as an Intervention for Radiation Therapy-Associated Toxicities: Review and Profile of Avasopasem Manganese as a Treatment Option for Radiation-Induced Mucositis. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 1021-1029.	2.0	15
12	A hypothesis for the pathogenesis of radiation-induced oral mucositis: when biological challenges exceed physiologic protective mechanisms. Implications for pharmacological prevention and treatment. <i>Supportive Care in Cancer</i> , 2021, 29, 4939-4947.	1.0	18
13	Healthcare-associated infections among patients hospitalized for cancers of the lip, oral cavity and pharynx. <i>Infection Prevention in Practice</i> , 2021, 3, 100115.	0.6	3
14	GM-1111 reduces radiation-induced oral mucositis in mice by targeting pattern recognition receptor-mediated inflammatory signaling. <i>PLoS ONE</i> , 2021, 16, e0249343.	1.1	6
15	Concordance of the WHO, RTOG, and CTCAE v4.0 grading scales for the evaluation of oral mucositis associated with chemoradiation therapy for the treatment of oral and oropharyngeal cancers. <i>Supportive Care in Cancer</i> , 2021, 29, 6061-6068.	1.0	20
16	Disparities in the geospatial distribution of dentists in the United States in 2017. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2021, 131, e114.	0.2	0
17	The Path to an Evidence-Based Treatment Protocol for Extraoral Photobiomodulation Therapy for the Prevention of Oral Mucositis. <i>Frontiers in Oral Health</i> , 2021, 2, 689386.	1.2	8
18	The application of Omics to accelerate precision medicine in Supportive Care in Cancer. <i>Supportive Care in Cancer</i> , 2021, 29, 7143-7144.	1.0	2

#	ARTICLE	IF	CITATIONS
19	Validation of a Monte Carlo Modelling Based Dosimetry of Extraoral Photobiomodulation. <i>Diagnostics</i> , 2021, 11, 2207.	1.3	1
20	Could the impact of photobiomodulation on tumor response to radiation be effected by tumor heterogeneity?. <i>Supportive Care in Cancer</i> , 2020, 28, 423-424.	1.0	13
21	Randomized Phase 2 Trial of a Novel Clonidine Mucoadhesive Buccal Tablet for the Amelioration of Oral Mucositis in Patients Treated With Concomitant Chemoradiation Therapy for Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 320-328.	0.4	15
22	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i> , 2020, 126, 4423-4431.	2.0	540
23	Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action. <i>Supportive Care in Cancer</i> , 2020, 28, 5059-5073.	1.0	40
24	An update on pharmacotherapies in active development for the management of cancer regimen-associated oral mucositis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 541-548.	0.9	21
25	Enhanced oral hygiene interventions as a risk mitigation strategy for the prevention of non-ventilator-associated pneumonia: a systematic review and meta-analysis. <i>British Dental Journal</i> , 2020, 228, 615-622.	0.3	14
26	Disparities in Oral Cancer Screening Among Dental Professionals: NHANES 2011–2016. <i>American Journal of Preventive Medicine</i> , 2019, 57, 447-457.	1.6	24
27	Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3256-3265.	0.8	77
28	OUP accepted manuscript. <i>Journal of the National Cancer Institute Monographs</i> , 2019, 2019, .	0.9	34
29	Phase II investigational oral drugs for the treatment of radio/chemotherapy induced oral mucositis. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 147-154.	1.9	17
30	Predicting mucositis risk associated with cytotoxic cancer treatment regimens: rationale, complexity, and challenges. <i>Current Opinion in Supportive and Palliative Care</i> , 2018, 12, 198-210.	0.5	18
31	Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm. <i>Cancer Medicine</i> , 2018, 7, 240-253.	1.3	23
32	Phase 1b/2a Trial of the Superoxide Dismutase Mimetic GC4419 to Reduce Chemoradiotherapy-Induced Oral Mucositis in Patients With Oral Cavity or Oropharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 427-435.	0.4	63
33	Impact of the insurance type of head and neck cancer patients on their hospitalization utilization patterns. <i>Cancer</i> , 2018, 124, 760-768.	2.0	23
34	Biomarkers Associated with Lymphedema and Fibrosis in Patients with Cancer of the Head and Neck. <i>Lymphatic Research and Biology</i> , 2018, 16, 516-524.	0.5	18
35	The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. <i>Oncologist</i> , 2017, 22, 343-350.	1.9	57
36	Safety and tolerability of topical clonazepam solution for management of oral dysesthesia. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2017, 124, 146-151.	0.2	11

#	ARTICLE	IF	CITATIONS
37	Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients. <i>Biotechnology Reports</i> (Amsterdam, Netherlands), 2017, 15, 24-26.	2.1	14
38	The Chicken or the Egg? Changes in Oral Microbiota as Cause or Consequence of Mucositis During Radiation Therapy. <i>EBioMedicine</i> , 2017, 18, 7-8.	2.7	25
39	Genomic data integration in chronic lymphocytic leukemia. <i>Journal of Gene Medicine</i> , 2017, 19, e2936.	1.4	20
40	Extraorally delivered photobiomodulation therapy for prevention of oropharyngeal mucositis in pediatric patients undergoing hematopoietic cell transplantation. <i>Proceedings of SPIE</i> , 2017, , .	0.8	0
41	Exploring Genetic Attributions Underlying Radiotherapy-Induced Fatigue in Prostate Cancer Patients. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 326-339.	0.6	7
42	Oral health status and risk of bacteremia following allogeneic hematopoietic cell transplantation. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2017, 124, 253-260.	0.2	16
43	[P3â€™091]: EFFECTIVE ANALYSIS OF GENE EXPRESSION FOR THE DISCOVERY OF BIOMARKERS AND THERAPEUTIC TARGETS FOR ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P968.	0.4	0
44	New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury. <i>Frontiers in Pharmacology</i> , 2017, 8, 354.	1.6	165
45	Could the PI3K canonical pathway be a common link between chronic inflammatory conditions and oral carcinogenesis?. <i>Journal of Oral Pathology and Medicine</i> , 2016, 45, 469-474.	1.4	10
46	Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. <i>Journal of Biotechnology</i> , 2016, 239, 115-125.	1.9	43
47	Pharmacotherapy for the management of cancer regimen-related oral mucositis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1801-1807.	0.9	61
48	Impact of Microarray Preprocessing Techniques in Unraveling Biological Pathways. <i>Journal of Computational Biology</i> , 2016, 23, 957-968.	0.8	9
49	Design of Biomedical Robots for Phenotype Prediction Problems. <i>Journal of Computational Biology</i> , 2016, 23, 678-692.	0.8	25
50	Toxicities associated with head and neck cancer treatment and oncology-related clinical trials. <i>Current Problems in Cancer</i> , 2016, 40, 244-257.	1.0	18
51	Topical Clonazepam Solution for Management of Burning Mouth Syndrome. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2016, 122, e110.	0.2	0
52	Cytokineâ€mediated blood brain barrier disruption as a conduit for cancer/chemotherapyâ€associated neurotoxicity and cognitive dysfunction. <i>International Journal of Cancer</i> , 2016, 139, 2635-2645.	2.3	108
53	Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations. <i>Supportive Care in Cancer</i> , 2016, 24, 2781-2792.	1.0	179
54	Could the biological robustness of low level laser therapy (Photobiomodulation) impact its use in the management of mucositis in head and neck cancer patients. <i>Oral Oncology</i> , 2016, 54, 7-14.	0.8	92

#	ARTICLE	IF	CITATIONS
55	A Novel Peptide for Simultaneously Enhanced Treatment of Head and Neck Cancer and Mitigation of Oral Mucositis. <i>PLoS ONE</i> , 2016, 11, e0152995.	1.1	17
56	Mucositis. <i>Current Opinion in Oncology</i> , 2015, 27, 159-164.	1.1	213
57	Genomics, Personalized Medicine, and Supportive Cancer Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 9-16.	1.8	9
58	Toll-like receptor 4 signaling: A common biological mechanism of regimen-related toxicities. <i>Cancer Treatment Reviews</i> , 2015, 41, 122-128.	3.4	34
59	Mammalian Target of Rapamycin Inhibitorâ€“Associated Stomatitis in Hematopoietic Stem Cell Transplantation Patients Receiving Sirolimus Prophylaxis for Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 503-508.	2.0	21
60	Oral Medicine referrals at a hospital-based practice in the United States. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2015, 119, 423-429.	0.2	23
61	Unanticipated frequency and consequences of regimen-related diarrhea in patients being treated with radiation or chemoradiation regimens for cancers of the head and neck or lung. <i>Supportive Care in Cancer</i> , 2015, 23, 433-439.	1.0	13
62	Current understanding of the relationship between periodontal and systemic diseases. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2015, 36, 150-158.	0.5	30
63	An Outcomes Study of 40 Years of Graduates of a General Practice Dental Residency. <i>Journal of Dental Education</i> , 2015, 79, 888-896.	0.7	3
64	Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update. <i>World Journal of Gastroenterology</i> , 2015, 21, 11793.	1.4	29
65	An Outcomes Study of 40 Years of Graduates of a General Practice Dental Residency. <i>Journal of Dental Education</i> , 2015, 79, 888-96.	0.7	0
66	Mechanisms of cellular fibrosis associated with cancer regimen-related toxicities. <i>Frontiers in Pharmacology</i> , 2014, 5, 51.	1.6	59
67	Local and Systemic Pathogenesis and Consequences of Regimen-Induced Inflammatory Responses in Patients with Head and Neck Cancer Receiving Chemoradiation. <i>Mediators of Inflammation</i> , 2014, 2014, 1-14.	1.4	48
68	Multiâ€“institutional, randomized, doubleâ€“blind, placeboâ€“controlled trial to assess the efficacy of a mucoadhesive hydrogel (MuGard) in mitigating oral mucositis symptoms in patients being treated with chemoradiation therapy for cancers of the head and neck. <i>Cancer</i> , 2014, 120, 1433-1440.	2.0	57
69	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i> , 2014, 120, 1453-1461.	2.0	838
70	Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 675-680.	1.1	28
71	Randomized double-blind placebo-controlled trial of celecoxib for oral mucositis in patients receiving radiation therapy for head and neck cancer. <i>Oral Oncology</i> , 2014, 50, 1098-1103.	0.8	25
72	Emerging evidence on the pathobiology of mucositis. <i>Supportive Care in Cancer</i> , 2013, 21, 2075-2083.	1.0	121

#	ARTICLE	IF	CITATIONS
73	Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. <i>Cancer</i> , 2013, 119, 4268-4276.	2.0	107
74	Oral Mucositis in Head and Neck Cancer: Risk, Biology, and Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e236-e240.	1.8	43
75	Oral Mucositis in Head and Neck Cancer: Risk, Biology, and Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e236-e240.	1.8	55
76	Predicting risk of chemotherapy-induced side effects in patients with colon cancer with single-nucleotide polymorphism (SNP) Bayesian networks (BNs).. <i>Journal of Clinical Oncology</i> , 2013, 31, 344-344.	0.8	3
77	Long-term symptom burden and orodental health of oropharyngeal cancer (OPC) survivors following treatment with chemoradiotherapy (CRT) or sequential therapy (ST).. <i>Journal of Clinical Oncology</i> , 2013, 31, 9530-9530.	0.8	0
78	Randomized double-blind placebo-controlled trial of celecoxib for radiation-induced oral mucositis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9620-9620.	0.8	0
79	Community-based dental evaluation program for hematopoietic cell transplantation.. <i>Journal of Clinical Oncology</i> , 2013, 31, 143-143.	0.8	1
80	A clinically translatable mouse model for chemotherapy-related fatigue. <i>Comparative Medicine</i> , 2013, 63, 491-7.	0.4	36
81	A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapy. <i>Supportive Care in Cancer</i> , 2012, 20, 1797-1804.	1.0	19
82	New Frontiers in Mucositis. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 545-551.	1.8	21
83	A Comparison and Assessment of Scoring Scales for Mucositis. , 2012, , 39-46.		3
84	SNP-Based Bayesian Networks Define Oral Mucositis Risk in Patients Receiving Stomatotoxic Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 735-735.	0.6	0
85	Inflammation and Genetic Risk Indicators for Early Periodontitis in Adults. <i>Journal of Periodontology</i> , 2011, 82, 588-596.	1.7	13
86	The Quest for Effective Treatments of Mucositis. <i>The Journal of Supportive Oncology</i> , 2011, 9, 170-171.	2.3	7
87	Oral mucositis. <i>Anti-Cancer Drugs</i> , 2011, 22, 607-612.	0.7	148
88	Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis. <i>Core Evidence</i> , 2010, 4, 199.	4.7	42
89	Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. <i>Cancer</i> , 2010, 116, 210-215.	2.0	131
90	Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study. <i>Supportive Care in Cancer</i> , 2010, 18, 95-103.	1.0	39

#	ARTICLE	IF	CITATIONS
91	Regimen-related gastrointestinal toxicities in cancer patients. <i>Current Opinion in Supportive and Palliative Care</i> , 2010, 4, 26-30.	0.5	43
92	Reduced Infection and Mucositis In Chemotherapy-Treated Animals Following Innate Defense Modulation Using a Novel Drug Candidate.. <i>Blood</i> , 2010, 116, 3781-3781.	0.6	0
93	Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. <i>Oral Oncology</i> , 2009, 45, 164-172.	0.8	177
94	Mucositis: The impact, biology and therapeutic opportunities of oral mucositis. <i>Oral Oncology</i> , 2009, 45, 1015-1020.	0.8	379
95	Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 239-251.	1.1	147
96	Oral and Maxillofacial Medicine. <i>Oral Diseases</i> , 2009, 15, 118-118.	1.5	2
97	Links between regimen-related toxicities in patients being treated for colorectal cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2009, 3, 50-54.	0.5	19
98	Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 33-41.	1.1	179
99	Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy. <i>Cancer</i> , 2008, 113, 2704-2713.	2.0	310
100	Management of Oral Mucositis in Patients Who Have Cancer. <i>Dental Clinics of North America</i> , 2008, 52, 61-77.	0.8	423
101	Efficacy of Superoxide Dismutase Mimetic M40403 in Attenuating Radiation-Induced Oral Mucositis in Hamsters. <i>Clinical Cancer Research</i> , 2008, 14, 4292-4297.	3.2	79
102	Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation. <i>International Journal of Radiation Biology</i> , 2008, 84, 401-412.	1.0	29
103	Mucositis: biology and management. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2007, 15, 123-129.	0.8	104
104	The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: Pathobiology, animal models and cytotoxic drugs. <i>Cancer Treatment Reviews</i> , 2007, 33, 448-460.	3.4	235
105	Updated clinical practice guidelines for the prevention and treatment of mucositis. <i>Cancer</i> , 2007, 109, 820-831.	2.0	692
106	Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. <i>Supportive Care in Cancer</i> , 2007, 15, 491-496.	1.0	147
107	Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. <i>The Journal of Supportive Oncology</i> , 2007, 5, 231-5.	2.3	27
108	New thoughts on the pathobiology of regimen-related mucosal injury. <i>Supportive Care in Cancer</i> , 2006, 14, 516-518.	1.0	47

#	ARTICLE	IF	CITATIONS
109	Can oral glutamine prevent mucositis in children undergoing hematopoietic stem-cell transplantation?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 244-245. Introduction; <i>Oral Care in Advanced Disease; Supportive Care for the Renal Patient; Handbook of Opioid Bowel Syndrome</i> Oral Care in Advanced Disease. Edited by Andrew Davies and Ilora Finley . New York: Oxford University Press, 2005, 221 pp., \$75.00	4.3	3
110	Supportive Care for the Renal Patient. Edited by E. Joanna Chambers , Michael Germain , and Edwina Brown . New York: Oxford University Press, 2004, 276 pp., \$95.00 (hardcover) <i>Handbook of Opioid Bowel Syndrome</i> . Edited by Chun-Su Yuan , M.D., Ph.D. <i>Bin. Journal of Palliative Medicine</i> , 2006, 9, 814-817.	0.6	0
111	Is oral mucositis an inevitable consequence of intensive therapy for hematologic cancers?. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 134-135.	4.3	18
112	Dimensional Stability of the Alveolar Ridge After Implantation of a Bioabsorbable Bone Graft Substitute: A Radiographic and Histomorphometric Study in Rats. <i>Journal of Oral Implantology</i> , 2005, 31, 68-76.	0.4	5
113	Single-Dose Prevention or Short-Term Treatment with Fibroblast Growth Factor-20 (CG53135-05) Reduces the Severity and Duration of Oral Mucositis. <i>Supportive Cancer Therapy</i> , 2005, 2, 122-127.	0.3	6
114	Mucositis after Allogeneic Hematopoietic Stem Cell Transplantation: A Cohort Study of Methotrexate- and Non-Methotrexate-Containing Graft-versus-Host Disease Prophylaxis Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 383-388.	2.0	98
115	Palifermin in Myelotoxic Therapy-Induced Oral Mucositis. <i>Drugs</i> , 2005, 65, 2147-2149.	4.9	1
116	Oral Mucositis (OM) and Outcomes of Allogeneic (AL) Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hematologic Malignancies.. <i>Blood</i> , 2005, 106, 3126-3126.	0.6	0
117	Oral Mucositis (OM) and Outcomes of Autologous (AU) Hematopoietic Stem Cell Transplantation (HSCT) Following High-Dose Melphalan (MP) Conditioning for Multiple Myeloma (MM).. <i>Blood</i> , 2005, 106, 1343-1343.	0.6	0
118	New trends in the management of oral mucositis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2005, 3 Suppl 1, S54-6.	2.3	0
119	The pathobiology of mucositis. <i>Nature Reviews Cancer</i> , 2004, 4, 277-284.	12.8	1,050
120	Perspectives on cancer therapy-induced mucosal injury. <i>Cancer</i> , 2004, 100, 1995-2025.	2.0	1,214
121	Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. <i>Cancer</i> , 2004, 100, 2026-2046.	2.0	691
122	Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 328-336.	2.0	136
123	Pathobiology of mucositis. <i>Seminars in Oncology Nursing</i> , 2004, 20, 11-15.	0.7	146
124	Oral Mucositis Incidence and Severity after Methotrexate and Non-Methotrexate Containing GVHD Prophylaxis Regimens.. <i>Blood</i> , 2004, 104, 351-351.	0.6	3
125	Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.. <i>Blood</i> , 2004, 104, 1227-1227.	0.6	0
126	Oral mucositis in cancer therapy. <i>The Journal of Supportive Oncology</i> , 2004, 2, 3-8.	2.3	88

#	ARTICLE	IF	CITATIONS
127	The prevention and treatment of radiotherapy-induced xerostomia. <i>Seminars in Radiation Oncology</i> , 2003, 13, 302-308.	1.0	24
128	How should we measure and report radiotherapy-induced xerostomia?. <i>Seminars in Radiation Oncology</i> , 2003, 13, 226-234.	1.0	135
129	Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. <i>Cancer</i> , 2003, 98, 406-412.	2.0	51
130	Antimicrobial therapy to prevent or treat oral mucositis. <i>Lancet Infectious Diseases</i> , The, 2003, 3, 405-412.	4.6	115
131	A Phase III, Randomized, Double-blind, Placebo-controlled, Multinational Trial of Iseganan for the Prevention of Oral Mucositis in Patients Receiving Stomatotoxic Chemotherapy (PROMPT-CT Trial). <i>Leukemia and Lymphoma</i> , 2003, 44, 1165-1172.	0.6	60
132	Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis. <i>Clinical Cancer Research</i> , 2003, 9, 3454-61.	3.2	40
133	T^h B¹ R^{ole for} N^{uclear} F^{actor} K^{appa} B ⁱⁿ D^{isease and its} P^{otential} I^{nvolve}ment in<sup> M^{ucosal} I^{njury} A^{ssociated with} A^{nti-neoplastic} T^{herapy}. <i>Critical Reviews in Oral Biology and Medicine</i> , 2002, 13, 289-300.	4.4	189
134	Nanoparticulate Hydroxyapatite Enhances the Bioactivity of a Resorbable Bone Graft. <i>Materials Research Society Symposia Proceedings</i> , 2002, 735, 641.	0.1	0
135	Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. <i>Blood</i> , 2002, 100, 3479-3482.	0.6	167
136	Oral complications of cancer therapy. <i>Oncology</i> , 2002, 16, 680-6; discussion 686, 691-2, 695.	0.4	53
137	Oral Mucositis and the Clinical and Economic Outcomes of Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2001, 19, 2201-2205.	0.8	552
138	Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. , 1999, 85, 2103-2113.		305
139	Risk factors affecting hospital length of stay in patients with odontogenic maxillofacial infections. <i>Journal of Oral and Maxillofacial Surgery</i> , 1996, 54, 1386-1391.	0.5	75
140	TRANSPLANTATION OF POLARIZED TYPE 2 DONOR T CELLS REDUCES MORTALITY CAUSED BY EXPERIMENTAL GRAFT-VERSUS-HOST DISEASE1. <i>Transplantation</i> , 1996, 62, 1278-1285.	0.5	57
141	Section Reviews: Biologicals & Immunologicals: Pharmacological attenuation of chemotherapy-induced oral mucositis. <i>Expert Opinion on Investigational Drugs</i> , 1996, 5, 1155-1162.	1.9	4
142	A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. <i>Cancer</i> , 1993, 72, 1612-1617.	2.0	214
143	Assessment of the need for treatment of postendodontic asymptomatic periapical radiolucencies in bone marrow transplant recipients. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1993, 76, 45-48.	0.6	35
144	Effect of medical status on dental procedure time. <i>Special Care in Dentistry</i> , 1992, 12, 71-73.	0.4	7

#	ARTICLE	IF	CITATIONS
145	Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1992, 74, 749-755.	0.6	83
146	An animal model for mucositis induced by cancer chemotherapy. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1990, 69, 437-443.	0.6	163
147	The role of herpes simplex virus in the development of oral mucositis in bone marrow transplant recipients. <i>Cancer</i> , 1990, 66, 2375-2379.	2.0	50
148	In vivo and in vitro effects of β -carotene and algae extracts in murine tumor models. <i>Nutrition and Cancer</i> , 1989, 12, 371-380.	0.9	7
149	Impact of improved dental services on the frequency of oral complications of cancer therapy for patients with non-head-and-neck malignancies. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1988, 65, 19-22.	0.6	63
150	Preservation of the alveolar ridge with hydroxyapatite-collagen implants in rats. <i>Journal of Prosthetic Dentistry</i> , 1988, 60, 729-734.	1.1	14
151	An analysis of dental services based in the emergency room. <i>Special Care in Dentistry</i> , 1988, 8, 106-108.	0.4	16
152	Manual of oral and maxillofacial surgery. <i>Special Care in Dentistry</i> , 1988, 8, 40-40.	0.4	0
153	Hospital dentistry: is there a future?. <i>Special Care in Dentistry</i> , 1987, 7, 243-243.	0.4	0
154	Increased efficiency of immunotherapy using irradiated tumor cells. <i>Cancer Immunology, Immunotherapy</i> , 1987, 24, 68-71.	2.0	2
155	Oral complications of multimodality therapy for advanced squamous cell carcinoma of head and neck. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1986, 61, 139-141.	0.6	22
156	Significance of the head and neck in late infection in renal transplant recipients. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1986, 62, 524-528.	0.6	1
157	Healing of Spontaneous Periodontal Defects in Dogs Treated with Xenogeneic Demineralized Bone. <i>Journal of Periodontology</i> , 1985, 56, 470-479.	1.7	14
158	Severe oral hemorrhage and sepsis following bone marrow transplant failure. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1983, 56, 483-486.	0.6	6
159	Interaction of Ia antigen-bearing polymorphonuclear leukocytes and murine splenocytes. <i>Inflammation</i> , 1983, 7, 25-33.	1.7	7
160	The antigenicity of electrocauterized allogeneic tumor cells in mice. <i>Journal of Surgical Research</i> , 1982, 33, 17-22.	0.8	2
161	Effects of supernatants of polymorphonuclear neutrophils recruited by different inflammatory substances on mitogen responses of lymphocytes. <i>Inflammation</i> , 1982, 6, 1-11.	1.7	18
162	Alterations in the Oral Mucosa Caused by Chemotherapeutic Agents.. <i>The Journal of Dermatologic Surgery and Oncology</i> , 1981, 7, 1019-1025.	0.8	113

#	ARTICLE	IF	CITATIONS
163	Utilization of inpatient dental consultation services. <i>Special Care in Dentistry</i> , 1981, 1, 18-21.	0.4	10
164	The Presence of Lymphoblasts in the Gingival Crevice of Children With Acute Lymphoblastic Leukemia. <i>Journal of Periodontology</i> , 1981, 52, 276-279.	1.7	4
165	MODIFICATION OF IN VITRO AND IN VIVO IMMUNE FUNCTION BY ACUTE INFLAMMATORY CELLS. Transplantation, 1980, 30, 244-250.	0.5	10
166	Oral pathoses as diagnostic indicators in leukemia. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1980, 50, 134-139.	0.6	70
167	Relationship of oral complications to peripheral blood leukocyte and platelet counts in patients receiving cancer chemotherapy. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1979, 48, 21-28.	0.6	97
168	Chlorhexidine-Induced Lingual Keratosis and Dysplasia in Rats. <i>Journal of Periodontology</i> , 1978, 49, 585-591.	1.7	18
169	THE ROLE OF EFFECTOR CELLS AND ANTISERUM IN THE INHIBITION OF CELL-MEDIATED CYTOTOXICITY OF ALLOGENEIC TUMOR CELLS. Transplantation, 1976, 22, 52-60.	0.5	2
170	The incidence of mast cells in selected oral lesions. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1972, 34, 245-248.	0.6	10
171	In Vitro Effects of Isobutyl Cyanoacrylate on Four Types of Bacteria. <i>Journal of Dental Research</i> , 1971, 50, 1557-1558.	2.5	36